The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Pelusi, Serena ^a   Girelli, Domenico ^b   Rametta, Raffaela ^a   Campostrini, Natascia ^b   Alfieri, Carlo ^a   Traglia, Michela ^c,d   Dongiovanni, Paola ^a   Como, Giovanna ^a   Toniolo, Daniela ^c,d   Camaschella, Clara ^c   Messa, Piergiorgio ^a   Fargion, Silvia ^a   Valenti, Luca ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d CNR   (Italy)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin; Genetics; Hemodialysis; Hepcidin; Hfe gene; Inflammation; Iron; Matriptase 2; Tmprss6

Indexed keywords

C REACTIVE PROTEIN; FERRIC GLUCONATE; FERRITIN; HEPCIDIN;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROPOIESIS; FEMALE; GENE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEMOCHROMATOSIS; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; TMPRSS6 GENE;

ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRON; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84874090861     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-48     Document Type: Article

References (35)

1. Overview of anemia associated with chronic renal disease: primary and secondary mechanisms. Paganini EP, Semin Nephrol 1989 9 3 8 2669084 (Pubitemid 19200762)
2. Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications. Canavesi E, Valenti L, Hemodialysis.-Different Aspects, Maria Goretti P, Available from: http://www.intechopen.com/books/hemodialysis-different-aspects/ modulation-of-iron-metabolism-and-hepcidin-release-by-hfe-mutations-in-chronic- hemodialysis-patients ISBN 978-953-307-315-6 10.5772/22735
3. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Babitt JL, Lin HY, Am J Kidney Dis 2010 55 726 741 10.1053/j.ajkd.2009. 12.030 20189278
4. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH, Nephrol Dial Transplant 2004 19 141 149 10.1093/ndt/gfg493 14671049 (Pubitemid 38072625)
5. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A, Am J Nephrol 2008 28 115 121 10.1159/000109968 17943020 (Pubitemid 350126501)
6. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Valenti L, Girelli D, Valenti GF, Castagna A, Como G, Campostrini N, Rametta R, Dongiovanni P, Messa P, Fargion S, Clin J Am Soc Nephrol 2009 4 1331 1337 10.2215/CJN.01370209 19541813
7. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I, Blood 2006 108 1381 1387 10.1182/blood-2005-10-4043 16621968 (Pubitemid 44232041)
8. Hepcidin as well as TNF-{alpha} are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, Yahiro M, Nanami M, Otaki Y, Hasuike Y, Nephrol Dial Transplant 2011 26 2663 2667 10.1093/ndt/gfq760 21245128
9. Hepcidin in anemia and inflammation in chronic kidney disease. Malyszko J, Mysliwiec M, Kidney Blood Press Res 2007 30 15 30 10.1159/000098522 17215586
10. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Morelle J, Labriola L, Jadoul M, Kidney Int 2009 76 1116 author reply 1116 19876058
11. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, Reis F, Teixeira F, Miranda V, do Sameiro Faria V, Loureiro A, Acta Haematol 2009 122 226 229 10.1159/000253590 19887781
12. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, Porto G, Blood 2008 111 5727 5733 10.1182/blood-2007-08- 106195 18326822
13. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, Westerman M, Ganz T, Nemeth E, Piperno A, Camaschella C, Haematologica 2011 96 500 506 10.3324/haematol.2010.033449 21173098
14. HFE Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study. Valenti L, Valenti G, Como G, Santorelli G, Dongiovanni P, Rametta R, Fracanzani AL, Tavazzi D, Messa PG, Fargion S, Am J Nephrol 2008 28 311 316 10.1159/000111387 18025780
15. HFE gene mutations and oxidative stress influence serum ferritin, associated with vascular damage, in hemodialysis patients. Valenti L, Valenti G, Como G, Burdick L, Santorelli G, Dongiovanni P, Rametta R, Bamonti F, Novembrino C, Fracanzani AL, Am J Nephrol 2007 27 101 107 10.1159/000099635 17299255 (Pubitemid 46364547)
16. Time-dependent associations between iron and mortality in hemodialysis patients. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG, J Am Soc Nephrol 2005 16 3070 3080 10.1681/ASN.2005040423 16033854 (Pubitemid 44743505)
17. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, Frugoni C, Fracanzani AL, Fargion S, Arterioscler Thromb Vasc Biol 2011 31 683 690 10.1161/ATVBAHA.110.214858 21183736
18. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Rametta R, Nutr Metab Cardiovasc Dis 2010 21 568 575 20392616
19. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G, Blood 2010 115 3616 3624 10.1182/blood-2009-09-245977 20053755
20. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, Sala C, Masciullo C, Vigano F, Buetti I, Pistis G, J Med Genet 2011 48 629 634 10.1136/jmedgenet-2011-100061 21785125
21. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Nai A, Pagani A, Silvestri L, Campostrini N, Corbella M, Girelli D, Traglia M, Toniolo D, Camaschella C, Blood 2011 118 4459 4462 10.1182/blood-2011-06-364034 21873547
22. Iron-refractory iron deficiency anemia. Finberg KE, Semin Hematol 2009 46 378 386 10.1053/j.seminhematol.2009.06.006 19786206
23. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Benyamin B, Ferreira MA, Willemsen G, Gordon S, Middelberg RP, McEvoy BP, Hottenga JJ, Henders AK, Campbell MJ, Wallace L, Nat Genet 2009 41 1173 1175 10.1038/ng.456 19820699
24. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Chambers JC, Zhang W, Li Y, Sehmi J, Wass MN, Zabaneh D, Hoggart C, Bayele H, McCarthy MI, Peltonen L, Nat Genet 2009 41 1170 1172 10.1038/ng.462 19820698
25. Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. Valenti L, Fracanzani A, Rametta R, Fraquelli M, Soverini G, Pelusi S, Dongiovanni P, Conte D, Fargion S, J Hepatol 2012 57 1319 1325 10.1016/j.jhep.2012.07.041 22885719
26. The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease. Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S, PLoS One 2012 7 48804 10.1371/journal.pone.0048804 23144979
27. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S, Nephrol Dial Transplant 2004 19 Suppl 2 i1 ii47 15206425
28. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, Maggioni M, Fracanzani AL, Fargion S, J Hepatol 2010 53 927 933 10.1016/j.jhep.2010.05.023 20739079
29. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, Martinelli N, Lupo A, Olivieri O, Girelli D, J Biomed Biotechnol 2010 2010 329646 20414466
30. Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera study. Campostrini N, Traglia M, Martinelli N, Corbella M, Cocca M, Manna D, Castagna A, Masciullo C, Silvestri L, Olivieri O, J Proteomics 2012 76 28 35 22951294
31. Mechanisms of anemia in CKD. Babitt JL, Lin HY, J Am Soc Nephrol 2012 23 1631 1634 10.1681/ASN.2011111078 22935483
32. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB, Clin J Am Soc Nephrol 2010 5 1010 1014 10.2215/CJN.08161109 20299375
33. Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients? Bratescu LO, Barsan L, Munteanu D, Stancu S, Mircescu G, J Ren Nutr 2010 20 77 S83 10.1053/j.jrn.2010.06.006 20797577
34. Serum hepcidin: reference ranges and biochemical correlates in the general population. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW, Blood 2011 117 218 e225 10.1182/blood-2011-02-337907 21527524
35. Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. Delbini P, Vaja V, Graziadei G, Duca L, Nava I, Refaldi C, Cappellini MD, Br J Haematol 2010 151 281 Äì284 10.1111/j.1365-2141.2010.08349. x 20738301